SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Perform and lowers the price target from $60 to $56.
Credit Suisse Maintains Outperform on Carlisle Companies, Lowers Price Target to $350
Credit Suisse analyst Daniel Oppenheim maintains Carlisle Companies (NYSE:CSL) with a Outperform and lowers the price target from $363 to $350.